T hree classes of medication have been implicated in causing or worsening existing ophthalmological conditions, including alpha-blockers such as tamsulosin, PDE5-inhibitors such as sildenafil, and anticholinergics, including oxybutynin. Some associations have been purely theoretical, others based on case reports with no suggestion of a mechanism. The maxim 'prescribe with caution' may be sound advice from a medico-legal point of view, but it is not a practical guide for clinicians keen to minimise harm to their patients. This article discusses each class in turn, presenting the evidence in the literature to date, and summarises the recommendations for their use with regards to their ophthalmological side-effects.
ALPHA-BLOCKERS AND FLOPPY IRIS SYNDROME
Alpha-blockers are widely prescribed in the UK. It is estimated that in the age group 70-79 around 46% of men describe having classical lower urinary tract symptoms (LUTS), 1 and with drug treatment being first line for these symptoms a significant proportion of these patients will be prescribed an alpha-blocker. Highly selective alpha-blockers such as tamsulosin have been found to have a relatively low side-effect profile, with only around 5% of patients experiencing symptoms of dizziness, although there are varying reports on the incidence of retrograde ejaculation.
Another common complaint associated with advancing age is the development of cataracts. This clouding of the lens is a significant cause of visual impairment in older age, and over 300 000 eyes are operated on in the UK per year.
2 During cataract surgery the pupil must be dilated with antimuscarinic eye drops, such as tropicamide, to allow access to the crystalline lens in the anterior chamber of the eye. During surgery intraoperative floppy iris syndrome (IFIS) can occur ( Figure 1 ) and this has been linked to concurrent alpha-blocker use. IFIS is a triad of progressive intraoperative pupillary constriction, iris prolapse and a flaccid, unpredictable iris.
The first suggestion of an association between alpha-blockers and IFIS came from Chang and Campbell who reported that 96% of their cohort who developed IFIS were, or had been, on tamsulosin. 3 Other alpha-blockers were not implicated in this study.
The association seems to be particularly strong with tamsulosin. A retrospective study from Canada found the incidence of IFIS to be 86% in tamsulosin-treated patients compared to 15% in patients on alfuzosin. 4 However, while the incidence of IFIS in the general population has been reported to be between 0.6 and 3.7%, reports on the incidence of IFIS in patients exposed to tamsulosin vary widely from 37.9% to 100%.
3,5-9 IFIS has been found to be associated with other alpha-blockers including doxazocin, although much less strongly. 10, 11 The proposed mechanism for IFIS with alpha-blockers is through the blockade of the alpha-1 receptors, specifically alpha-1a receptors, which are found both in the prostate and in the iris. In the eye the dilator muscles of the iris are under sympathetic control, mediated by these alpha-1 receptors, while the radial constrictor muscles are under parasympathetic control. It is thought that drugs like tamsulosin block the alpha-receptors responsible for pupil dilatation, thereby resulting in unopposed parasympathetic action with a constricted pupil and an unstable and 'floppy' iris. Other alpha-blockers have varying selectivity for this receptor subtype, which may explain the variation in the incidence of IFIS with different alpha-blockers.
One problem in establishing causality is that the effect is not dose dependent; 12 nor does it seem to be correlated with how long the drug is taken or the time since last use. IFIS has been reported occurring several years after stopping tamsulosin, 3 suggesting a permanent effect on the iris. However, numerous studies have looked at whether patients on tamsulosin experiencing IFIS in one eye also experience this in the contralateral eye during a subsequent operation. This does not seem to be the case, suggesting that the effect of tamsulosin is unlikely to be a permanent one. 12, 13 The time taken for tamsulosin to affect the iris is also disputed. Chang et al suggested that it would only occur after a minimum of 2 weeks of taking the drug. 3 Others have found detectable effects on iris dilatation intraoperatively after only 2 days of taking tamsulosin. 14 Chang et al also carried out a study where they stopped tamsulosin 1-8 weeks prior to surgery and found no significant difference in the severity of IFIS. 15 It appears then that while there is clear evidence for a role for tamsulosin in the development of IFIS the mechanism is not clear-cut, nor can the outcomes be predicted based on the duration of therapy or the dose. The question is whether alphablockers should be stopped prior to surgery if there is no reliable preoperative method to predict whether IFIS will occur? Some have raised the possibility that the concurrent use of anticholinergic eye drops such as atropine to dilate the iris while withholding alpha-blockers will push some patients into urinary retention. There is very little evidence to support this; indeed, anticholinergics have been used increasingly with and without alpha-blockers to treat LUTS with low rates of retention. 16 The recommendations for alpha-blockers in relation to cataract surgery are listed in Box 1.
PDE5-INHIBITORS AND NON-ARTERITIC ANTERIOR ISCHAEMIC OPTIC NEUROPATHY
Non-arteritic anterior ischaemic optic neuropathy (NAION) is a neuropathy that is associated with compromised blood supply to the optic nerve (Figure 2) . It is associated with cardiovascular risk factors and can be thought of as an optic nerve 'stroke', although the cause of this condition is far from clear. It presents as sudden, unilateral, complete or partial loss of vision, usually on waking. Few patients become permanently blind and 42% of patients improve markedly within 6 months, although 12% of patients develop worsening visual impairment and 15% of patients find their other eye becomes involved within 5 years. 17, 18 There are no clinically effective treatments for this condition.
It is thought that NAION develops in patients with already 'crowded' optic disks, where a large number of nerve fibres are packed into a small space. This, combined with existing cardiovascular risk factors, reduces flow to the optic nerve, particularly at night when arterial hypoperfusion is most likely to occur. PDE5-inhibitors have been developed specifically to increase arterial flow to endorgans due to their vasodilatory action. Despite this apparently contradictory mechanism there have been suggestions from a number of small studies that PDE5-inhibitors increase the risk of NAION. McGwin et al reported that in a case-control series of 76 patients there was a statistically significant difference only if the patient had suffered a previous myocardial infarction. 19 Other reports have been from case studies alone.
PDE5-inhibitors, such as sildenafil, are very commonly used drugs for erectile dysfunction, and they are used particularly in patients with existing cardiovascular disease. This means that there is significant overlap between patients using PDE5-inhibitors and those experiencing NAION.
Despite this, there is no clear evidence that PDE5-inhibitors can in any way be implicated in the development of NAION. A post-marketing safety database of sildenafil reported no NAION in almost 40 000 patients. 20 Gorkin et al reported that the incidence of NAION in sildenafil users was not significantly different to the incidence in the general population of American men over 50. 21 Sildenafil is associated with mild and transient visual changes, particularly with blue-green colour discrimination. This is thought to be due to the crossinhibition of PDE6, which is found in the photoreceptor cells in the retina. The recommendations on prescribing of PDE5-inhibitors in relation to NAION are given in Box 2.
ANTICHOLINERGIC THERAPY AND GLAUCOMA
Anticholinergics are first-line treatments for the management of overactive bladder (OAB) and urinary urge incontinence (UUI) and work by inhibiting M3 receptors in the detrusor smooth muscle of the bladder. Anticholinergic side-effects, such as dry mouth and constipation, arise due to the interaction of these drugs with muscarinic receptors in other tissues such as the mouth and bowel.
Acute-angle closure glaucoma (AACG) is a sight-threatening condition whereby the outflow of aqueous humour from the anterior chamber of the eye is blocked, leading to a catastrophic rise in intraocular pressure and eventually infarction of the optic nerve (Figure 3) . Angle closure manifests usually in patients already suffering from chronic glaucoma with narrow drainage channels, also known as 'narrow angles', which are at risk of suddenly being closed. Patients already being treated for glaucoma will be regularly followed up to assess the size of these 'angles', to establish whether they are at risk of angle closure.
One well-documented precipitating factor pushing patients from chronic glaucoma into angle closure is exposure to dark. Pupillary dilatation in these conditions leads to a further narrowing of the angle, occasionally completely blocking the outflow channels and causing a rapid rise in intraocular pressure. Treatment includes various topical eye drops to increase the outflow of aqueous humour and reduce its production, intravenous acetazolamide, and eventually surgical management with peripheral iridotomy to create a new tract for the drainage of aqueous humour.
Ophthalmologists are therefore always careful to assess the depth of the angle before administering topical dilating drops with anticholinergic activity, such as atropine, when examining the eye. It follows then that other anticholinergics could potentially also cause pupillary dilatation and therefore put patients at risk of developing AACG.
Although this mechanism sounds entirely plausible, in clinical practice this effect is extremely rare when using urological drugs. Only one case report exists of an 80-year-old lady taking oxybutynin 2.5mg twice daily who developed unilateral AACG that was successfully treated with iridotomy. 22 However, because of these concerns, all major trials involving anticholinergics have excluded patients with narrow angles, including the Overactive Bladder: Judging Effective Control and Treatment (OBJECT) study and the Antimuscarinic Clinical Effectiveness Trial (ACET). Not one patient in these large trials has reported AACG as an adverse event. 23, 24 It is therefore extremely difficult to assess the incidence of AACG in patients taking anticholinergic drugs, as high-risk patients have generally been excluded from trials. It is worth noting that the actual reported incidence of AACG with anticholinergics still remains incredibly low. In Japan a review of 367 patients started on oxybutynin asked each patient about their glaucoma history and, where unclear, patients were sent to an ophthalmologist for clarification. Patients with open-angle glaucoma and treated, closed-angle glaucoma were started on oxybutynin with no adverse effects. 25 Recommendations on the use of anticholinergic drugs in glaucoma are given in Box 3.
CONCLUSION
In summary, a whole range of potential ophthalmic complications have been associated with the use of urological drugs, although causality is far from proven in each case. Perhaps the most compelling case is for tamsulosin's effect on intraoperative behaviour of the iris, and ophthalmologists are well aware of the increased surgical complexity of these cases. In most centres, these cases will be performed by a senior surgeon. The evidence for the role of PDE5-inhibitors in NAION and anticholinergic drugs in glaucoma is far less convincing, and while a good history will help to identify the patients at risk, the actual incidence of ophthalmic side-effects is extremely low.
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